Dr Chirag Madaan, Dr Shruti Malik, Dr Divya Gautam


In present time, Carbapenem resistance is an emerging problem throughout the World and is an important threat to public health as well as treatment challenge to clinicians.


Carbapenem Cre Beta Lactamases Polymyxin

Full Text:



Bradley J. S., et al. 1999. Carbapenems in clinical practice: a guide to their use in serious infection. Int. J. Antimicrob. Agents 11:93–100.

Paterson D. L. 2000. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin. Microbiol. Infect. 6:460–463.

Torres J. A., Villegas M. V., Quinn J. P. 2007. Current concepts in antibiotic-resistant gram-negative bacteria. Expert Rev. Anti Infect. Ther. 5:833–843.

Queenan A. M., Bush K.. 2007. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev. 20:440–458, table of contents.

Limansky A. S., Mussi M. A., Viale A. M. 2002. Loss of a 29-kilodalton outer membrane protein in Acinetobacter baumannii is associated with imipenem resistance. J. Clin. Microbiol. 40:4776–4778.

Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53(1):60–67.

Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099–1106.

Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18.

Micozzi A, Gentile G, Minotti C, Cartoni C, Capria S, Ballaro D, Santilli S, Pacetti E, Grammatico S, Bucaneve G, et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect Dis. 2017;17(1):203.

Donkor E., Newman M.J., Tay S.C.K., Dayie N.T.K.D., Bannerman E., Olu-Taiwo M. Investigation into the risk of exposure to antibiotic residues contaminating meat and egg in Ghana. Food Control. 2011;22:869–873. doi: 10.1016/j.foodcont.2010.11.014.

Donkor E.S., Newman M.J., Yeboah-Manu D. Epidemiological aspects of non-human antibiotic usage and resistance: Implications for the control of antibiotic resistance in Ghana. Trop. Med. Int. Health. 2012;17:462–468. doi: 10.1111/j.1365-3156.2012.02955.x

Francis S. C, Eric S. D. Carbapenem Resistance: A Review. Med Sci (Basel). 2018 Mar; 6(1): 1.

Georgios M. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016 Feb; 3(1): 15–21.

Woodford N, Wareham DW, Guerra B, Teale C. Carbapenemase-producing Enterobacteriaceae and non-Enterobacteriaceae from animals and the environment: an emerging public health risk of our own making? J Antimicrob Chemother. 2013;69:287–91.

Patel G, Bonomo RA. “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol. 2013.

Ambler RP, Coulson AFW, Frere JM, Ghuysen JM, Joris B, Forsman M, Levesque RC, Tiraby G, Waley SG. A standard numbering scheme for the class A beta lactamases. Biochem J. 1991;276:269–70.

Queenan AM, Bush K. Carbapenemases: the versatile lactamases. Clin Microbiol Rev. 2007;20(23):440–58.

Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D -lactamases. Antimicrob Agents Chemother. 2010;54:24–38.

Canton R, Akova M, Carmeli Y et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 18(5), 413–431 (2012).

Moellering RC Jr. NDM-1–a cause for worldwide concern. N. Med. 363(25), 2377–2379 (2010).

Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin. Microbiol.Rev. 25(4), 682–707 (2012).

Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 17(10), 1791–1798 (2011).

Walsh TR. Emerging carbapenemases: a global perspective. Int. J. Antimicrob.Agents 36(Suppl. 36), S8–S14 (2010).

Cornaglia G, Giamarellou H, Rossolini GM. Metallo-beta-lactamases: a last frontier for beta-lactams? Lancet Infect. Dis. 11(5), 381–393 (2011).

Chen Z, Chen Y, Fang Y, et al. Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci Rep. 2015;5

Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72:29–39

Ni W, Han Y, Liu J, et al. Tigecycline treatment for Carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine. 2016;95 e3126.

Souli M, Karaiskos I, Masgala A, Galani L, Barmpouti E, Giamarellou H. Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2017;36:1305–1315.

Cprek JB, Gallagher JC. Ertapenem-containing double-Carbapenem therapy for treatment of infections caused by Carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015;60:669–673.


  • There are currently no refbacks.